AstraZeneca announced plans to create a Shanghai cell therapy research, development and manufacturing hub with capabilities spanning early R&D, clinical manufacturing and regulatory support for Asian markets. The facility is part of AstraZeneca’s broader multi‑billion dollar commitment to China and aims to support CAR‑T and other cell therapies, including programs acquired via prior deals such as Gracell and EsoBiotech. The company said the hub will enable regional production of cell therapies and accelerate development timelines for both oncology and autoimmune indications. AstraZeneca framed the investment as an effort to secure local manufacturing capacity and to engage with China’s rapidly expanding clinical trial ecosystem. The move expands multinational pharmaceutical footprints in China’s life‑sciences sector and underscores increasing industry focus on regional production, regulatory alignment, and in‑market cell therapy access.